Search
AstraZeneca, Daiichi hit first goal in pivotal breast cancer ADC trial
- Care For A Cure
- Sep 24, 2023
- 1 min read
AstraZeneca and Daiichi Sankyo are coming for Gilead Sciences' breast cancer business. The partners plan to file for approval of datopotamab deruxtecan (Dato-DXd) after linking their antibody-drug conjugate (ADC) to improved outcomes, although the immature overall survival (OS) data leave a key question unanswered.
Comentarios